Barriers and facilitators to the involvement of general practitioners in the prescription of buprenorphine

J Subst Use Addict Treat. 2024 Jan:156:209182. doi: 10.1016/j.josat.2023.209182. Epub 2023 Oct 18.

Abstract

Introduction: France has one of the highest opioid agonist treatment (OAT) coverage rates in the world. French general practitioners (GPs) are providing the majority of prescriptions. However, a fall in the number of GPs initiating buprenorphine has been observed over the last decade.

Methods: The objective of this study was to explore the obstacles and facilitators to the involvement of GPs in the prescription of buprenorphine. A qualitative study comprising 14 individual interviews and a focus group bringing together 5 GPs was conducted among GPs based in France between June 2021 and March 2022. We performed data analysis using a grounded theory methodology.

Results: The interviews showed a great diversity in the level of involvement of GPs, depending on their experience, their representations of patients with OUD, their mode of exercise, and their personal preferences. The negative representations of the patients associated with the feeling of physical and ethical endangerment, the feeling of powerlessness, the fear of a disruption of the practice and the feeling of incompetence appeared at the forefront of the difficulties stated. Conversely, the strengthening of initial training and the facilitation of access to self-training tools and multidisciplinarity, the consideration of opioid use disorder (OUD) as a chronic illness with the application of a patient-centered motivational approach, as well as the defining and respecting one's own limits when prescribing buprenorphine seem to be the keys to a balanced and fulfilling practice.

Conclusion: Raising awareness of the frequency of OUD appeared to be an additional lever to enhance the interest of the GPs concerned. Additional studies focusing on the evolution of professional practices would be necessary to extend these findings.

Keywords: Buprenorphine; General practitioners; Opioid use disorder; Primary care.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Buprenorphine* / therapeutic use
  • General Practitioners*
  • Humans
  • Opioid-Related Disorders* / drug therapy
  • Prescriptions
  • Professional Practice

Substances

  • Buprenorphine